Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".
作者信息
Hsu Yao-Chun, Chen Chi-Yi, Lin Jaw-Town
机构信息
Division of Gastroenterology and Hepatology, E-Da Hospital, Kaohsiung, Taiwan.
School of Medicine & Graduate Institute of Medicine, I-Shou University, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
Abstract
摘要
相似文献
1
Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".扩大慢性乙型肝炎的治疗适用范围：权衡益处、局限性与医疗可及性：致关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论的信函
Clin Mol Hepatol. 2025 Apr;31(2):e169-e172. doi: 10.3350/cmh.2024.1138. Epub 2024 Dec 23.
2
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".简化和扩大慢性乙型肝炎治疗的趋势：证据不断增加：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):603-605. doi: 10.3350/cmh.2024.0929. Epub 2024 Oct 29.
3
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".重新审视慢性乙型肝炎的治疗指征：TORCH-B 延续性研究的见解：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B 试验的延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
4
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".慢性乙型肝炎患者丙氨酸氨基转移酶轻度升高时对核苷（酸）类似物的治疗反应：致编辑的信，关于“丙氨酸氨基转移酶轻度升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的延续性研究”
Clin Mol Hepatol. 2025 Apr;31(2):e140-e142. doi: 10.3350/cmh.2024.0960. Epub 2024 Dec 3.
5
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.针对轻度转氨酶升高的慢性乙型肝炎的抗病毒治疗：TORCH-B试验的一项延续性研究。
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
6
Effectiveness of antiviral treatment in HBeAg-negative chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase: a retrospective study.抗病毒治疗对 HBeAg 阴性慢性乙型肝炎患者中丙氨酸氨基转移酶正常或轻度升高的疗效：一项回顾性研究。
BMC Gastroenterol. 2022 Aug 17;22(1):387. doi: 10.1186/s12876-022-02471-y.
7
Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase.对病毒血症水平高且血清转氨酶正常或轻度升高的儿童进行抗病毒治疗可实现慢性乙型肝炎的功能性治愈
J Clin Transl Hepatol. 2023 Oct 28;11(5):1011-1022. doi: 10.14218/JCTH.2023.00014. Epub 2023 Apr 10.
8
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.使用丙酚替诺福韦进行早期抗病毒治疗以预防慢性乙型肝炎且病毒血症为中度或高度的成人发生严重临床不良事件（ATTENTION）：一项随机对照试验的中期结果
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3.
9
Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels.慢性乙型肝炎病毒感染者伴持续正常或轻度氨基转移酶水平的管理。
J Cell Biochem. 2019 Apr;120(4):6632-6641. doi: 10.1002/jcb.27959. Epub 2018 Oct 28.
10
Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.开发和评估一种简单的治疗资格评分（HEPSANET），以在非洲分散乙型肝炎的护理：一项横断面研究。
Lancet Gastroenterol Hepatol. 2024 Apr;9(4):323-332. doi: 10.1016/S2468-1253(23)00449-1. Epub 2024 Feb 15.
本文引用的文献
1
Treatment response to nucleos(t)ide analogs in chronic hepatitis B with mildly elevated alanine aminotransferase: Letter to the editor on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".慢性乙型肝炎患者丙氨酸氨基转移酶轻度升高时对核苷（酸）类似物的治疗反应：致编辑的信，关于“丙氨酸氨基转移酶轻度升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的延续性研究”
Clin Mol Hepatol. 2025 Apr;31(2):e140-e142. doi: 10.3350/cmh.2024.0960. Epub 2024 Dec 3.
2
Reconsidering treatment indications for chronic hepatitis B: Insights from the TORCH-B roll-over study: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".重新审视慢性乙型肝炎的治疗指征：TORCH-B 延续性研究的见解：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B 试验的延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):606-609. doi: 10.3350/cmh.2024.1078. Epub 2024 Dec 3.
3
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on "Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial".简化和扩大慢性乙型肝炎治疗的趋势：证据不断增加：关于“轻度转氨酶升高的慢性乙型肝炎抗病毒治疗：TORCH-B试验的一项延续性研究”的社论
Clin Mol Hepatol. 2025 Apr;31(2):603-605. doi: 10.3350/cmh.2024.0929. Epub 2024 Oct 29.
4
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial.针对轻度转氨酶升高的慢性乙型肝炎的抗病毒治疗：TORCH-B试验的一项延续性研究。
Clin Mol Hepatol. 2025 Jan;31(1):213-226. doi: 10.3350/cmh.2024.0640. Epub 2024 Oct 17.
5
Guidelines for the Prevention, Diagnosis, Care and Treatment for People with Chronic Hepatitis B Infection (Text Extract): Executive Summary.慢性乙型肝炎感染者预防、诊断、照护及治疗指南（文本摘录）：执行摘要
Infect Dis Immun. 2024 Jul;4(3):103-105. doi: 10.1097/ID9.0000000000000128. Epub 2024 Jun 12.
6
Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B.替诺福韦酯对慢性乙型肝炎患者肝内病毒载量及肝脏免疫微环境的影响
Gut. 2025 Mar 6;74(4):628-638. doi: 10.1136/gutjnl-2024-332526.
7
Global burden of hepatitis B virus: current status, missed opportunities and a call for action.全球乙型肝炎病毒负担：现状、错失的机会和行动呼吁。
Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):524-537. doi: 10.1038/s41575-023-00760-9. Epub 2023 Apr 6.
8
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm.慢性乙型肝炎患者核苷（酸）类似物停药的安全性考虑：一、不造成伤害。
Clin Mol Hepatol. 2023 Oct;29(4):869-890. doi: 10.3350/cmh.2022.0420. Epub 2023 Mar 14.
9
Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment.整合的乙型肝炎病毒 DNA 在抗病毒治疗期间维持表面抗原的产生。
J Clin Invest. 2022 Sep 15;132(18). doi: 10.1172/JCI161818.
10
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?如何实现乙肝功能性治愈：停止核苷（酸）类似物，加用干扰素或开发新药？
J Hepatol. 2022 Jun;76(6):1249-1262. doi: 10.1016/j.jhep.2021.11.024.
Zotero 插件